Generate Biomedicines Inc’s Lock-Up Period Set To Expire on August 26th (NASDAQ:GENB)

Generate Biomedicines’ (NASDAQ:GENB) lock-up period is set to end on Wednesday, August 26th. Generate Biomedicines had issued 25,000,000 shares in its IPO on February 27th. The total size of the offering was $400,000,000 based on an initial share price of $16.00. After the expiration of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Morgan Stanley raised their price objective on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright increased their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Weiss Ratings began coverage on shares of Generate Biomedicines in a research note on Tuesday, August 11th. They issued a “sell (d)” rating on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Generate Biomedicines has an average rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Stock Performance

NASDAQ GENB opened at $15.99 on Friday. The business’s fifty day moving average is $14.89. The stock has a market cap of $2.05 billion and a price-to-earnings ratio of -10.06. Generate Biomedicines has a 52 week low of $11.00 and a 52 week high of $18.18.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The company had revenue of $6.31 million for the quarter. As a group, equities research analysts expect that Generate Biomedicines will post -2.29 earnings per share for the current fiscal year.

Institutional Trading of Generate Biomedicines

An institutional investor recently bought a new position in Generate Biomedicines stock. Bank of New York Mellon Corp purchased a new stake in shares of Generate Biomedicines Inc (NASDAQ:GENB) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 57,326 shares of the company’s stock, valued at approximately $967,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.